VIRP.PA
Strong BuyFull HouseFLAGVirbac SA · Healthcare · France · $3.1B · Avg Vol: $1M/d
Full House: Strong business, sensible price, market agrees. The rare full house.
Virbac has good quality at Q74 but value V58 and momentum M55 both fall short of the all-three-above-60 path with no corroborating filing. A 3.1% forward-EPS cut is separately adverse.
ABOUT VIRBAC SA
Read
Virbac SA is a leading independent global animal health company that develops, manufactures, and markets a comprehensive range of vaccines, pharmaceuticals, and nutritional products for companion and food-producing animals. The company's competitive moat is built on its broad product portfolio, strong brand equity among veterinarians, and global distribution footprint. Virbac operates as a highly agile, pure-play specialist in the resilient and growing animal health sector.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.2B | 1.2B | 1.4B | 1.5B | 6.4% | 1.5B | 1.5B | 1.6B | 5.9% |
| EPS (EUR) | 14.43 | 14.40 | 17.35 | 18.01 | 7.7% | 18.57 | 20.54 | 22.58 | 12.0% |
| Shares | 8.4M | 8.4M | 8.4M | 8.4M | -0.8% | 8.4M | — | — | — |
| Debt | 90.4M | 120.1M | 307.0M | 288.8M | 47.3% | 289.3M | — | — | — |
| Equity | 839.6M | 900.3M | 1.0B | 1.1B | 10.2% | — | — | — | — |
| Op CF | 99.0M | 118.6M | 204.2M | 199.0M | 26.2% | 198.8M | — | — | — |
| Inv CF | -54.8M | -121.9M | -428.7M | -198.6M | — | — | — | — | — |
| Fin CF | -34.8M | -2.7M | 138.6M | -9.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VIRP.PA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VIRP.PA | Virbac SA(you) | $3.1B | 88 | Strong Buy |
| SAN.PA | Sanofi | $107.2B | 93 | Strong Buy |
| CLARI.PA | Clariane SE | $1.6B | 79 | Buy |
| BIM.PA | bioMérieux S.A. | $10.3B | 85 | Strong Buy |
| VETO.PA | Vetoquinol SA | $946M | 97 | Strong Buy |
| EMEIS.PA | emeis Société anonyme | $2.4B | 58 | Hold |
| LBIRD.PA | Lumibird SA | $651M | 82 | Strong Buy |
| IPN.PA | Ipsen S.A. | $15.6B | 97 | Strong Buy |
| BOI.PA | Boiron SA | $509M | 99 | Strong Buy |
| LNA.PA | LNA Santé SA | $397M | 96 | Strong Buy |
Peer medians: ROE -42.5% · P/E 22.9x · Gross margin 73.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.